Hope S. Rugo
Impact in
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 551
- Cancer Treatment and Pharmacology 241
- HER2/EGFR in Cancer Research 194
- Cancer Immunotherapy and Biomarkers 77
- PARP inhibition in cancer therapy 51
-
- Advanced Breast Cancer Therapies 343
- Co-authors
- Véronique Dièras (63 shared papers)Hiroji Iwata (52 shared papers)Eric P. Winer (51 shared papers)Sherene Loi (45 shared papers)Seock‐Ah Im (45 shared papers)Peter Schmid (39 shared papers)Lisa M. Coussens (10 shared papers)Carlos H. Barrios (32 shared papers)
- Journals
- Journal of Clinical Oncology (284 papers)Cancer Research (84 papers)Annals of Oncology (79 papers)Breast Cancer Research and Treatment (49 papers)Clinical Cancer Research (24 papers)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Hope S. Rugo
817 papers receiving 45.8k citations
Hope S. Rugo's Hit Papers
Peers
Comparison fields: 5 of 164
- Oncology 24.9k
- Cancer Research 8.7k
- Pulmonary and Respiratory Medicine 13.6k
- Immunology 5.5k
- Genetics 2.2k
Countries citing papers authored by Hope S. Rugo
This map shows the geographic impact of Hope S. Rugo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hope S. Rugo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hope S. Rugo more than expected).
Fields of papers citing papers by Hope S. Rugo
This network shows the impact of papers produced by Hope S. Rugo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hope S. Rugo. The network helps show where Hope S. Rugo may publish in the future.
Co-authors
The 25 scholars most cited alongside Hope S. Rugo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 857 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 3084 |
| 2 | Palbociclib and Letrozole in Advanced Breast Cancer Hit paper breakdown → | 2016 | 1929 |
| 3 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2019 | 1644 |
| 4 | Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation Hit paper breakdown → | 2018 | 1450 |
| 5 | Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy Hit paper breakdown → | 2011 | 1325 |
| 6 | Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer Hit paper breakdown → | 2005 | 1006 |
| 7 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 877 |
| 8 | Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells Hit paper breakdown → | 2014 | 775 |
| 9 | Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer Hit paper breakdown → | 2010 | 704 |
| 10 | Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual Hit paper breakdown → | 2017 | 676 |
| 11 | T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 Hit paper breakdown → | 2018 | 675 |
| 12 | Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2022 | 654 |
| 13 | Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2019 | 624 |
| 14 | Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy Hit paper breakdown → | 2010 | 576 |
| 15 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Hit paper breakdown → | 2018 | 537 |
| 16 | The cancer glycocalyx mechanically primes integrin-mediated growth and survival Hit paper breakdown → | 2014 | 531 |
| 17 | Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer Hit paper breakdown → | 2009 | 504 |
| 18 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer Hit paper breakdown → | 2017 | 502 |
| 19 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 482 |
| 20 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer Hit paper breakdown → | 2015 | 464 |
About Hope S. Rugo
Hope S. Rugo is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Genetics, having authored 857 papers that have together received 46.6k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (343 papers), Cancer Treatment and Pharmacology (241 papers), HER2/EGFR in Cancer Research (194 papers), Breast Cancer Treatment Studies (114 papers), Cancer Immunotherapy and Biomarkers (77 papers), Cancer Genomics and Diagnostics (51 papers), PARP inhibition in cancer therapy (51 papers) and PI3K/AKT/mTOR signaling in cancer (41 papers). The work is most often cited by research in Oncology (24.9k citations), Cancer Research (8.7k citations), Pulmonary and Respiratory Medicine (13.6k citations), Immunology (5.5k citations) and Genetics (2.2k citations). Hope S. Rugo has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Véronique Dièras, Hiroji Iwata, Eric P. Winer, Sherene Loi, Seock‐Ah Im, Peter Schmid, Lisa M. Coussens, Carlos H. Barrios, Sylvia Adams and Leisha A. Emens. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.